Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of lewy body disease

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Masliah, Eliezer ^a,b   Rockenstein, Edward ^a   Mante, Michael ^a   Crews, Leslie ^b   Spencer, Brian ^a   Adame, Anthony ^a   Patrick, Christina ^a   Trejo, Margarita ^a   Ubhi, Kiren ^a   Rohn, Troy T ^c   Mueller Steiner, Sarah ^d   Seubert, Peter ^d   Barbour, Robin ^d   McConlogue, Lisa ^d   Buttini, Manuel ^d   Games, Dora ^d   Schenk, Dale ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BOISE STATE UNIVERSITY   (United States)

^d ELAN PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ALPHA SYNUCLEIN MONOCLONAL ANTIBODY; CALPAIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BIOACCUMULATION; CARBOXY TERMINAL SEQUENCE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; DRUG BINDING; DRUG EFFICACY; DRUG PENETRATION; IN VIVO STUDY; MAZE TEST; MOUSE; NERVE FIBER; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; SYNAPSE; ANIMAL; DISEASE MODEL; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYSOSOME; METABOLISM; METHODOLOGY; NERVE DEGENERATION; PATHOLOGY; RAT; TRANSGENIC MOUSE; TUMOR CELL LINE;

ALPHA-SYNUCLEIN; ANIMALS; ANTIBODIES, MONOCLONAL; BEHAVIOR, ANIMAL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; IMMUNIZATION, PASSIVE; IMMUNOHISTOCHEMISTRY; LEWY BODY DISEASE; LYSOSOMES; MAZE LEARNING; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; RATS;

EID: 79955757052     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019338     Document Type: Article

References (63)

1. McKeith IG, (2000) Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol Clin 18: 865-902.
2. Weinreb P, Zhen W, Poon A, Conway K, Lansbury PJ, (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochem 35: 13709-13715.
3. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, et al. (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14: 467-475.
4. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM, (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20: 3214-3220.
5. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, et al. (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10: 717-721.
6. Iwatsubo T, Yamaguchi H, Fujimuro M, Yokosawa H, Ihara Y, et al. (1996) Purification and characterization of Lewy bodies from brains of patients with diffuse Lewy body disease. AmJPathol 148: 1517-1529.
7. Lansbury PT Jr, (1999) Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci U S A 96: 3342-3344.
8. Trojanowski JQ, Lee VM, (1998) Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 55: 151-152.
9. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, et al. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 97: 571-576.
10. Tsigelny IF, Bar-On P, Sharikov Y, Crews L, Hashimoto M, et al. (2007) Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. Febs J 274: 1862-1877.
11. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr, (2002) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418: 291.
12. Crews L, Spencer B, Desplats P, Patrick C, Paulino A, et al. (2010) Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS ONE In press.
13. Crews L, Tsigelny I, Hashimoto M, Masliah E, (2009) Role of synucleins in Alzheimer's disease. Neurotox Res 16: 306-317.
14. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D, (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305: 1292-1295.
15. Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, et al. (2009) Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci 29: 13578-13588.
16. Langston JW, (2006) The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 59: 591-596.
17. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, et al. (2005) Effects of alpha-Synuclein Immunization in a Mouse Model of Parkinson's Disease. Neuron 46: 857-868.
18. Zhou C, Emadi S, Sierks MR, Messer A, (2004) A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther 10: 1023-1031.
19. Emadi S, Liu R, Yuan B, Schulz P, McAllister C, et al. (2004) Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 43: 2871-2878.
20. Benner EJ, Mosley RL, Destache CJ, Lewis TB, Jackson-Lewis V, et al. (2004) Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 101: 9435-9440.
21. Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, et al. (2008) Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS ONE 3: e3135.
22. Tsigelny IF, Sharikov Y, Miller MA, Masliah E, (2008) Mechanism of alpha-synuclein oligomerization and membrane interaction: theoretical approach to unstructured proteins studies. Nanomedicine 4: 350-357.
23. Lee HJ, Patel S, Lee SJ, (2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 25: 6016-6024.
24. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, et al. (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 106: 13010-13015.
25. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, et al. (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 287: 65-67.
26. Noguchi-Shinohara M, Tokuda T, Yoshita M, Kasai T, Ono K, et al. (2009) CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res 1251: 1-6.
27. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, et al. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science 287: 1265-1269.
28. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, et al. (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68: 568-578.
29. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, et al. (2001) beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 98: 12245-12250.
30. Rockenstein E, Crews L, Masliah E, (2007) Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv Drug Deliv Rev 59: 1093-1102.
31. Dickson DW, (2001) Alpha-synuclein and the Lewy body disorders. Curr Opin Neurol 14: 423-432.
32. Dufty BM, Warner LR, Hou ST, Jiang SX, Gomez-Isla T, et al. (2007) Calpain-Cleavage of {alpha}-Synuclein: Connecting Proteolytic Processing to Disease-Linked Aggregation. Am J Pathol 170: 1725-1738.
33. Rockenstein E, Mallory M, Mante M, Sisk A, Masliah E, (2001) Early formation of mature amyloid-b proteins deposits in a mutant APP transgenic model depends on levels of Ab1-42. J neurosci Res 66: 573-582.
34. Roeder LM, Poduslo SE, Tildon JT, (1982) Utilization of ketone bodies and glucose by established neural cell lines. J Neurosci Res 8: 671-682.
35. Takenouchi T, Hashimoto M, Hsu L, Mackowski B, Rockenstein E, et al. (2001) Reduced neuritic outgrowth and cell adhesion in neuronal cells transfected with human a-synuclein. MolCell Neurosci 17: 141-150.
36. Hashimoto M, Takenouchi T, Rockenstein E, Masliah E, (2003) Alpha-synuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease. J Neurochem 85: 1468-1479.
37. Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, et al. (2008) The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest 118: 2190-2199.
38. Koob AO, Ubhi K, Paulsson JF, Kelly J, Rockenstein E, et al. (2010) Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol 221: 267-274.
39. Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, et al. (2010) Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 74: 97-109.
40. Rhodes SL, Sinsheimer JS, Bordelon Y, Bronstein JM, Ritz B, (2011) Replication of GWAS Associations for GAK and MAPT in Parkinson's Disease. Ann Hum Genet 75: 195-200.
41. Li W, West N, Colla E, Pletnikova O, Troncoso JC, et al. (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A 102: 2162-2167.
42. Hoyer W, Cherny D, Subramaniam V, Jovin TM, (2004) Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 43: 16233-16242.
43. Takeda A, Hashimoto M, Mallory M, Sundsmo M, Hansen L, et al. (1998) Abnormal distribution of the non-Ab component of Alzheimer's disease amyloid precursor/a-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. LabInvest 78: 1169-1177.
44. Fortin DL, Nemani VM, Voglmaier SM, Anthony MD, Ryan TA, et al. (2005) Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci 25: 10913-10921.
45. Kramer ML, Schulz-Schaeffer WJ, (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27: 1405-1410.
46. de Laureto PP, Tosatto L, Frare E, Marin O, Uversky VN, et al. (2006) Conformational properties of the SDS-bound state of alpha-synuclein probed by limited proteolysis: unexpected rigidity of the acidic C-terminal tail. Biochemistry 45: 11523-11531.
47. Kim HY, Cho MK, Kumar A, Maier E, Siebenhaar C, et al. (2009) Structural properties of pore-forming oligomers of alpha-synuclein. J Am Chem Soc 131: 17482-17489.
48. van Rooijen BD, Claessens MM, Subramaniam V, (2008) Membrane binding of oligomeric alpha-synuclein depends on bilayer charge and packing. FEBS Lett 582: 3788-3792.
49. van Rooijen BD, Claessens MM, Subramaniam V, (2009) Lipid bilayer disruption by oligomeric alpha-synuclein depends on bilayer charge and accessibility of the hydrophobic core. Biochim Biophys Acta 1788: 1271-1278.
50. Lee HJ, Suk JE, Bae EJ, Lee JH, Paik SR, et al. (2008) Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol 40: 1835-1849.
51. Lee HJ, Suk JE, Bae EJ, Lee SJ, (2008) Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem Biophys Res Commun 372: 423-428.
52. Lee SJ, (2008) Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. J Mol Neurosci 34: 17-22.
53. Salem SA, Allsop D, Mann DM, Tokuda T, El-Agnaf OM, (2007) An investigation into the lipid-binding properties of alpha-, beta- and gamma-synucleins in human brain and cerebrospinal fluid. Brain Res 1170: 103-111.
54. Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L, (2009) Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS ONE 4: e5515.
55. Xilouri M, Vogiatzi T, Vekrellis K, Stefanis L, (2008) alpha-synuclein degradation by autophagic pathways: a potential key to Parkinson's disease pathogenesis. Autophagy 4: 917-919.
56. Bussiere T, Bard F, Barbour R, Grajeda H, Guido T, et al. (2004) Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol 165: 987-995.
57. Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, et al. (2005) Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci 25: 9096-9101.
58. Lemere CA, Maier M, Jiang L, Peng Y, Seabrook TJ, (2006) Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res 9: 77-84.
59. Schenk DB, Seubert P, Grundman M, Black R, (2005) A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. Neurodegener Dis 2: 255-260.
60. Sigurdsson EM, (2008) Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis 15: 157-168.
61. Sigurdsson EM, (2009) Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res 6: 446-450.
62. Pankiewicz J, Prelli F, Sy MS, Kascsak RJ, Kascsak RB, et al. (2006) Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci 23: 2635-2647.
63. Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, et al. (2005) Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci U S A 102: 11563-11568.